STM:新策略让乳腺癌告别“骨转移”

2016-05-28 佚名 生物探索

5月25日,杜克癌症研究所的科学家在Science Translational Medicine揭示了乳腺癌骨转移的另一个关键分子,并提出阻止乳腺癌骨转移的策略。 去年,科学家在《Nature》上揭示了乳腺癌细胞分泌蛋白lysyl oxidase(LOX)经血液循环到达骨骼,产生溶骨作用,从而帮助乳腺癌细胞在骨骼中转移。5月25日,杜克癌症研究所的科学家在 Science Translati

5月25日,杜克癌症研究所的科学家在Science Translational Medicine揭示了乳腺癌骨转移的另一个关键分子,并提出阻止乳腺癌骨转移的策略。

去年,科学家在《Nature》上揭示了乳腺癌细胞分泌蛋白lysyl oxidase(LOX)经血液循环到达骨骼,产生溶骨作用,从而帮助乳腺癌细胞在骨骼中转移。5月25日,杜克癌症研究所的科学家在 Science Translational Medicine 揭示了乳腺癌骨转移的另一个关键分子,并提出阻止乳腺癌骨转移的策略。

通过对小鼠的多年试验,科学家找到了一种策略既能预防乳腺癌细胞进入骨髓又能将其“驱赶”至血液中,使其更容易被摧毁。研究人员认为如果该研究结果能在其他动物和人体试验中复制,那么将给乳腺癌的治疗带来新的途径。

本研究资深作者,杜克癌症研究所血液系统恶性肿瘤及细胞疗法助理教授Dorothy A. Sipkins医学博士表示,“临床研究发现,乳腺癌可在早期被发现并治疗,但一个无疾病症状的患者,在10年或15年后,也可能出现疾病复发,且最常见的肿瘤转移部位是骨骼。”

在该研究中,研究人员描述了激素受体阳性乳腺癌细胞如何在血液和组织中“漫步”,他们发现这些癌细胞在寻找骨髓中包含E-selectin分子的特殊血管,并借助其表面特殊分子与E-selectin分子的结合进入骨骼中的海绵组织,且通常情况下这些细胞可潜伏多年。

为告别乳腺癌骨转移提供策略

根据美国临床肿瘤学会,激素受体阳性乳腺癌是最常见的乳腺癌类型,借助人体雌激素或孕激素来生长。本文资深作者Sipkins医学博士说,“在人类患者中,这些休眠细胞可在后期复苏并造成转移癌复发,且无法治愈。人类乳腺癌骨髓活检显示,即使在非常早期的癌症阶段,”漫游“的癌细胞(或微转移)就已经拥有独特的方式离开乳腺进入骨髓。”

研究人员表示,“如今我们知道了这些癌细胞如何进入骨骼,同时我们还确定了其锚定骨骼的重要机制。在该研究中,我们通过小鼠试验提供了新的策略——在休眠细胞扎根及复发前在分子水平上对其进行干预。”

策略之一是寻找一种方法来抑制E-selectin分子,这有助于限制癌细胞进入骨骼以及复发的能力。在该研究中,研究人员选用的E-selectin抑制剂为GMI-1271,该分子目前正用于人体临床试验中,研究人员发现该化合物能成功阻止乳腺癌细胞进入小鼠的骨髓中。

由于乳腺癌细胞扩散至骨骼可发生在疾病被诊断前的早期阶段里,因此研究人员还研究了一种策略将乳腺癌细胞从骨骼中“踢开”,使其返回到血液中。为了实现该目的,研究人员给小鼠注射plerixafor,plerixafor是一种用于人骨骼中的药剂,目的是将干细胞推入血液中。研究人员发现,plerixafor能使处于休眠状态的乳腺癌细胞从骨组织中流出并进入血液中。研究人员推测,将这些休眠的癌细胞从骨骼“驱赶”至血液,可增加其被免疫系统(化疗或激素)杀死的概率。

Sipkins说,“我们希望通过了解乳腺癌细胞如何在体内迁徙以及它们的生命周期如何,从而找出更有效的治疗方法,我们希望在老鼠身上做更多的研究,为人类研究打更好的基础。”

原始出处:

Price TT, Burness ML, Sivan A, Warner MJ, Cheng R, Lee CH, Olivere L, Comatas K, Magnani J, Kim Lyerly H, Cheng Q, McCall CM, Sipkins DA.

Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.

Sci Transl Med. 2016 May 25;8(340):340ra73. doi: 10.1126/scitranslmed.aad4059.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-10-02 gdsun
  3. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-31 stomach

    关注能否在临床中开展研究!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-31 stomach

    关注能否在临床中开展研究!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-29 shineshinelv

    期待下一步研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-29 shineshinelv

    期待下一步研究

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-29 明崖

    期待进一步研究

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-28 qq1e1c69fe

    希望早日实现临床应用

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=138074, encodeId=ce931380e434, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:57 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677977, encodeId=151216e7977d6, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sun Oct 02 08:53:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87720, encodeId=645f8e7207b, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:34:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87719, encodeId=4aab8e719b4, content=关注能否在临床中开展研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574A6B851C0291840.jpg, createdBy=cb1b1723481, createdName=stomach, createdTime=Tue May 31 08:33:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478374, encodeId=b3a414e8374c2, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Mon May 30 01:53:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87426, encodeId=290d8e42611, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:33:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87425, encodeId=35758e42594, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160529/IMG574AD2984A0809025.jpg, createdBy=33fb1613507, createdName=shineshinelv, createdTime=Sun May 29 19:32:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87407, encodeId=aad58e40795, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun May 29 12:15:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87365, encodeId=b3108e36556, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87366, encodeId=a1c98e3666c, content=希望早日实现临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da51712760, createdName=qq1e1c69fe, createdTime=Sat May 28 21:08:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-28 qq1e1c69fe

    希望早日实现临床应用

    0

相关资讯

Ann Surg Oncol:保乳术后,乳腺导管原位癌的复发和患者年龄有关?

乳腺钼靶被应用于乳腺癌筛查已长达30年,筛查意识的提高,导致乳腺导管原位癌的检出率逐年升高。保乳手术及保乳术后联合辅助治疗等,已作为标准的治疗方案被广泛应用于乳腺导管原位癌的治疗。Patricia A. Cronin博士等,对乳腺导管原位癌的患者进行了回顾,发现肿瘤的复发,与患者年龄、辅助治疗方案等相关因素有关。 Patricia A. Cronin博士等研究者,对1978年~2000年

JMC:一种靶向Src的乳腺癌的潜在药物被发现

英国爱丁堡大学23日发布一项研究成果介绍说,该校研究人员领衔的团队找到一种化合物,它能在实验室环境中有效抑制乳腺癌细胞的生长。科学家有望基于这一发现开发出新一代乳腺癌治疗药物。 据研究人员介绍,他们利用一种先进的成像技术,能够将化合物作用于癌细胞的过程可视化。在这种技术的辅助下,研究人员筛选出名为“eCF506”的化合物,它能够针对乳腺癌细胞生长和扩散的关键分子“Src酪氨酸激酶”发挥作用。

重磅!卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功,上半年向CFDA提交新药申请

日本药企卫材(Eisai)近日宣布,在中国开展的有关新型抗癌药Halaven(eribulin mesylate,甲磺酸艾瑞布林)的一项乳腺癌III期临床研究(Study 304)获得成功。该研究在中国的局部复发或转移性乳腺癌女性患者中开展,数据显示,与抗肿瘤药长春瑞滨(vinorelbine)治疗组相比,Havalen治疗组无进展生存期(PFS)得到统计学意义的显著改善,

科学家发现阻止乳腺癌转移的新方法

杜克癌症研究所的科学家们乳腺癌细胞用于入侵小鼠骨髓的分子钥匙,入侵到骨髓后癌细胞就可以避免被化学疗法或激素疗法清除。通过多年在小鼠上的试验,科学家们找到了对抗这种转移的方式,不光以阻止癌细胞侵入骨髓,还可以将癌细胞冲到血液中,在血液中癌细胞就可以被药物破坏了。这些发现为那些最具毁灭性的乳腺癌提供了一些信息,这些癌细胞具有被打败后卷土重来的能力。研究人员希望这些发现,如果可以在其他动物和人类试验中重

Nature:大规模乳腺癌“蛋白质基因组学”被揭示

基于来自癌症基因组图谱(TCGA)计划的数据,一个多机构科学家小组完成了首个大规模的乳腺癌“蛋白质基因组学”(proteogenomic)研究,将一些DNA突变与蛋白质信号联系到一起,并帮助确定了一些驱动癌症的基因。这项研究旨在通过蛋白质和它们的修饰来更好地认识癌症。发表在5月25日《自然》(Nature)杂志上的研究论文,证实了相比于单独采用任一种分析方法,整合基因组和蛋白质组数据来生成更完

Am J Clin Nutr:维生素C和绝经后乳腺癌风险有什么关系

维生素C摄入量和乳腺癌风险之间的关系,在实验和流行病学研究中取得了相互矛盾的结果。因此研究者进行了一项研究,探究维生素C的摄入量和乳腺癌风险之间的关系,同时将膳食维生素C的摄入量考虑在内。1995-2008年期间,该研究共纳入了57,403名绝经后妇女,在随访的581,085人年期间,共发生了2482例浸润性乳腺癌。在1993-1995年,通过食物频率问卷调查获取参与者的膳食维生素C摄入情况,并在